Peter Schmid

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid, Hope S. Rugo, Sylvia Adams et al. · The Lancet Oncology · 2019 · 1.2K citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17